阿鲁米斯

最新新闻

• 评级变动
  Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS), Cabaletta Bio (CABA) and Capricor Therapeutics (CAPR)
  TipRanks · 2026/8/14
• 评级变动
  Analysts' Top Healthcare Picks: UniQure (QURE), Alumis Inc. (ALMS)
  TipRanks · 2026/9/3
• Raymond James Maintains Alumis(ALMS.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/3
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST) and Alumis Inc. (ALMS)
  TipRanks · 2026/9/3
• Wells Fargo Sticks to Its Buy Rating for Alumis Inc. (ALMS)
  TipRanks · 2026/9/10
• H.C. Wainwright Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $15
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  Morgan Stanley Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $39
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alumis Inc. (ALMS) and Medtronic (MDT)
  TipRanks · 2026/9/2
• 评级变动
  Analysts' Opinions Are Mixed on These Healthcare Stocks: ProKidney (PROK), Crinetics Pharmaceuticals (CRNX) and Alumis Inc. (ALMS)
  TipRanks · 2026/8/11
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), Satellos Bioscience (MSLE) and Alumis Inc. (ALMS)
  TipRanks · 2026/8/14
• 评级变动
  A Quick Look at Today's Ratings for Alumis(ALMS.US), With a Forecast Between $15 to $37
  \u5e02\u573a\u8d44\u8baf · 2026/9/3
• 评级变动
  Guggenheim Keeps Their Buy Rating on Alumis Inc. (ALMS)
  TipRanks · 2026/8/14
• 评级变动
  Oppenheimer Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/7/16
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS) and AbCellera Biologics (ABCL)
  TipRanks · 2026/7/16
• Alumis(ALMS.US) Director Buys US$10.73 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• 公司公告
  Meiho Facility Works Ltd: It was selected as the commissioned contract reservation enterprise in the public offering proposal of "entrusting the construction consulting business of the alms-giving branch".
  JPX · 2022/8/18
• 评级变动
  Stifel Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $44
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  Guggenheim Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $34
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• Wells Fargo Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $25
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• 评级变动
  Alumis Inc. (ALMS) Receives a Rating Update From a Top Analyst
  TipRanks · 2026/8/13

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。